FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July 2020
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Board Committee
Changes
29 July 2020 07:00 BST
New Remuneration Committee Chairman
AstraZeneca PLC (the Company) today announced that the Board has
appointed Michel Demaré as a member and Chairman of the
Remuneration Committee, with effect from 1 August
2020.
Current Remuneration Committee Chairman, Graham Chipchase, will
step down from the Committee with effect from the same
date.
Leif Johansson, Chairman of AstraZeneca said "I would like to thank
Graham Chipchase sincerely on behalf of the Board for his excellent
leadership of the Remuneration Committee over the last five years.
It is one of the most challenging board roles and he has carried it
out successfully and assiduously. Given his extensive experience,
including on a UK public listed company remuneration committee, I
believe Michel Demaré is well-equipped to now lead the
Committee."
Mr Demaré has been a Non-Executive Director of the Company and
member of the Audit Committee since September 2019. For his
biographical details, please click here.
His experience includes service as a member of the Remuneration
Committee of the Board of Vodafone Group Plc since July 2018 and of
the Compensation Committee of the Board of Directors of UBS Group
AG from 2011 to 2019.
Mr Chipchase has chaired the AstraZeneca Remuneration Committee
since April 2015. He is the Company's senior independent
Non-Executive Director and a member of the Nomination and
Governance Committee. He has served as a Non-Executive Director
since April 2012.
At the Company's Annual General Meeting held on 29 April 2020,
resolutions to approve the Company's Annual Report on Remuneration
for the year ended 31 December 2019 and the new Remuneration Policy
were passed by votes of 96.65% and 94.71% respectively. The
resolution to re-elect Mr Chipchase as a Director of the Company
was passed by a vote of 99.48%.
AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines,
primarily for the treatment of diseases in three therapy areas -
Oncology, Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
29 July
2020
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|